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Background: Osteoporosis is common in patients with COPD. Previously we have reported
that loss of fat-free mass (FFM), measured by dual X-ray absorptiometry (DXA) is associated
with loss of bone mineral density (BMD). In addition, in patients with a low body mass index
(BMI) and a low FFM, all had evidence of bone thinning, 50% having osteopenia and 50%
osteoporosis. We explored the utility of different anthropometric measures in detecting
osteoporosis in a community-based COPD population.
Methods: Patients with confirmed COPD and not on long-term oral corticosteroids (n ¼ 58)
performed spirometry. They underwent nutritional assessment by skinfold anthropometry,
midarm circumference, calculation of both % ideal body weight (IBW) and BMI. All had DXA
assessment of BMD.
Results: A total of 58 COPD patients had anthropometric measurements taken, with a
mean age of 66.8 (SD 8.7) years, 31 (58%) were male, with a forced expiratory volume in 1 s
(FEV1) of 54.17 (20.18)% predicted. Osteoporosis was present at either the hip or lumbar
region in 14 patients (24%). The useful anthropometric measurements identifying those
with osteoporosis were both % IBW and BMI. The adjusted odds ratio for %IBW was 0.93 (95%
confidence interval (CI) 0.87, 0.99), p ¼ 0.016 and for BMI: 0.79 (0.64–0.98), p ¼ 0.03. The
receiver operating characteristics (ROC) score for both was 0.88, indicating a good fit.Elsevier Ltd. All rights reserved.
20716948; fax: +44 29 20716416.
.uk (D.J. Shale).
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Nutritional assessment, incorporating a calculation of their BMI or %IBW may confer an
additional benefit in detecting those at risk of osteoporosis and guide referral for BMD
measurement.
& 2008 Elsevier Ltd. All rights reserved.Introduction
COPD is associated with considerable morbidity and mortal-
ity.1 Awareness of the associated systemic complications
such as loss of skeletal muscle mass and function,
osteoporosis, insulin resistance and an increased risk of
cardiovascular disease, over and above the risk of smoking is
emerging.2–5 Osteoporosis is an important risk factor for the
development of hip, vertebral or long bone fracture which
could add further to disability and incapacity. Additionally a
hip fracture confers a greater mortality in the following
year.6
We have previously reported that there is a greater
prevalence of osteoporosis (32%) in patients with COPD
compared to 13% of controls.3 The patient population was
drawn predominantly from the community and therefore
included a large proportion of patients with mild-to-moderate
severity airways obstruction. None of them were or had been
on oral maintenance corticosteroids. This has been subse-
quently confirmed in different study populations.5,7
The universal standard method of determining bone
mineral density (BMD) and hence the presence of osteo-
porosis is dual energy X-ray absorptiometry (DXA) scanning.8
In the UK, DXA scanning demand for the service exceeds
availability. Diagnosis of COPD does not confer a ‘‘blanket’’
indication to perform a DXA, but identification of a higher
risk sub-group is required, given the prevalence of osteo-
porosis. Body composition appears to be a major determin-
ing factor for the presence of osteoporosis in the COPD
patient, not reflected to the same extent in lung function,
smoking pack years or gender.3
There are a number of ways of determining body
composition. A low fat-free mass (FFM) may be present in
the setting of maintained or a low body mass index (BMI) and
can represent a substantial proportion of COPD patients.1,3
Measurement of body composition in patients with COPD has
become an integral part to the COPD guidelines, with both
the NICE guidelines and the ATS/ERS guidelines alluding to
various methodologies.9,10 To promote their utility, any
nutritional tool needs to be reproducible, reliable and
inexpensive in order to facilitate its use within the
community. A history of weight loss, whilst being an
essential component of nutritional history taking, relies on
memory recall of the patient and is renowned for its
inaccuracy.
We assessed the utility of anthropometric measures of
body composition to identify individuals at risk of osteo-
porosis and who require a DXA scan in a subset of patients
from a larger group in a study of osteoporosis in COPD.3 We
selected the following measures that could be performed in
primary care; BMI, midarm circumference (MAC), height
squared ratio of FFM from skinfold anthropometry (SFA) and
the percentage of ideal body weight (IBW).Method
We studied a sub-group of 58 patients from a cohort of 81
enrolled in a study of osteoporosis in COPD.3 A total of 58
patients were selected purely on the grounds that they had
anthropometric measurements contemporaneous to DXA
determination of BMD. They were recruited when clinically
stable from primary care (n ¼ 51) and respiratory out-
patient clinics (n ¼ 7) and represented a sub-group of
patients with milder airways obstruction but similar other
demographics (age, gender, smoking habit and therapy). All
subjects were free from other chronic systemic inflamma-
tory disease, malignant disease, malabsorptive states and
none was on maintenance oral corticosteroids. All patients
had their diagnosis confirmed by history, examination,
spirometry and with a lack of reversibility to b2-agonist.
11
Patients’ age, gender, smoking pack years and daily dose of
inhaled steroids (mcg/day) were obtained. The study had
South East Wales Research Ethics agreement and all subjects
gave written informed consent.
Anthropometry
Height and weight (Seca, Germany) were measured with the
subject barefoot and wearing light, indoor clothing. The BMI
was calculated (kg/m2).
Skinfold anthropometry (SFA)
SFA was performed using Holtain callipers (Crymmych,
Pembrokeshire) at both the triceps and the sub-scapular
region (2 site skinfold measurement) and the subsequent %
body fat mass was determined using equations described in
detail in Nutrition and health in old age, 1979.12 From this,
the fat mass (FM) (kg) and FFM (body weightFM) was
subsequently calculated. The SFA–FFM was expressed as an
index (FFMI)—a height squared ratio, analogous to BMI
determination.13
Midarm circumference (MAC)
The MAC was measured using a tape measure at the
midpoint of the upper arm between the olecranon process
and acromion process.
Percentage ideal body weight (IBW)
The IBW was determined from the Metropolitan Life
Insurance Table 198314 by classing frame size as a ratio of
height (cm): wrist circumference (cm). The patient’s weight
was then classed as a percentage to the IBW. The IBW is
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size.
Bone mineral density (BMD) assessment—dual
energy X-ray absorptiometry (DXA)
BMD at the lumbar spine and hip were measured by DXA
(Hologic Discovery). The BMD is expressed as a T score, i.e.
the number of reference population standard deviations
from a reference mean value for young adults of the same
gender. Using WHO guidelines, osteoporosis was classed as a
T scoreo2.5 and osteopenia as a T scoreo1 but greater
than 2.5.15 T scoresX1 were classed as having a normal
BMD. A patient was classed as having osteoporosis if the T
scores suggested osteoporosis at either the lumbar spine
or hip.
Spirometry
Spirometry was performed to calculate forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC) and their
FEV1/FVC ratio (Vitalograph, Bucks, UK).
Statistical analysis
Data analysis was by Statistical Package for Social Science
(SPSS) version 14.0. Odds ratios (ORs) with 95% confidence
intervals (CIs) were used to investigate the univariate
association between each body composition measure per-
formed within the primary care sector and the presence of
osteoporosis. All body composition measures significant at
the 10% level (po0.10) were entered into a multivariate
logistic regression model to evaluate which were indepen-
dently associated with the presence of osteoporosis, after
adjusting for known risk factors of osteoporosis (age,
gender, FEV1, smoking pack years and daily dose of inhaled
steroids). The goodness-of-fit of each model was assessed
using the Hosmer–Lemeshow test.16 As a comparison,
multivariate linear regression was performed using BMDTable 1 Characteristics of patients with COPD.
All participants (n ¼ 58
Age (years) 66.8 (8.7)
Height (m) 1.65 (0.08)
BMI (kg/m2) 25.63 (4.46)
Inhaled steroid (mcg/day) 200 (0–1000)
Smoking habits
Current smoker n (%) 22 (38%)
Previous smoker n (%) 36 (62%)
Smoking pack years 35 (26.5–50)
Spirometry
FEV1% predicted 54.17 (20.18)
FEV1 (l) 1.36 (0.61)
Values are mean (SD) unless stated otherwise.
Inhaled corticosteroid ¼ betamethasone equiv. dose (mcg/day).
Median (interquartile range).(using T scores) as the main outcome, with R2 was used as a
test of goodness-of-fit.
The ability to discriminate between patients with
osteoporosis and patients with normal BMD or osteopenia
was quantified by using the area under the receiver
operating characteristics curve (ROC area). The ROC area
is a suitable measure to summarise the discriminative power
of a diagnostic model and can range from 0.5 (no
discrimination) to 1.0 (perfect discrimination). A value of
0.7–0.8 is considered to represent reasonable discrimination
and values 40.8 suggest good discrimination.17Results
The demographics of the patients are presented in Table 1.
Details of the mean BMD measurements, mean T scores and
numbers with osteoporosis, osteopenia and normal are
presented in Table 2. Osteoporosis was found in 14 patients
(24%) at either the total hip or the total lumbar spine region
and 29 patients (50%) had osteopenia at either of these two
sites. The remaining 15 (26%) patients had normal BMD at
both sites. Using a BMI ofo20 kg/m2,13 seven patients (12%)
had a low BMI.
The risk of osteoporosis was significantly increased in
patients with a lower BMI, %IBW, SFA FFMI or MAC (Table 3).
The risk of osteoporosis was significantly increased in female
patients and also for those with a low FEV1. After adjusting
for all covariates, COPD patients with a lower BMI or %IBW
were both found to be at an increased risk of osteoporosis,
whilst statistical significance was lost for MAC and SFA FFMI
(Table 4). The Hosmer–Lemeshow statistics of 7.39
(p ¼ 0.89) and 3.64 (p ¼ 0.50) for both BMI and %IBW,
respectively, suggests that there is no significant difference
between the predicted values from our models and those
observed.
Therefore, the adjusted %IBW and BMI models equally
predict the presence of osteoporosis in this sample of
patients with COPD, indicating a one unit increase in %IBW or
BMI predicts a reduced odds of osteoporosis or conversely) Males (n ¼ 31) Females (n ¼ 27)
69.3 (8.3) 63.9(8.5)
1.69 (0.06) 1.60 (0.06)
26.24 (4.37) 24.93 (4.55)
0 (0–1000) 400 (0–1000)
10 (32%) 12 (44%)
21 (68%) 15 (56%)
40 (30–50) 35 (23–40)
55.52 (20.10) 52.63 (20.54)
1.55 (0.66) 1.14 (0.47)
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Table 2 Bone mineral density measurements.
BMD (g/cm2) T score Osteoporosis Osteopenia Normal
Total lumbar spine region 0.92 (0.18) 1.40 (1.55) 13 (22%) 25 (43%) 20 (35%)
Total hip region 0.86 (0.18) 1.02 (1.29) 5 (9%) 30 (52%) 23 (39%)
Values are mean (SD) unless stated otherwise.
Table 3 Characteristics of COPD patients with and without osteoporosis and results of univariate analysis to investigate
predictors of osteoporosis.
Osteoporosis
(n ¼ 14)
Non-osteoporosis
(osteopenia/
normal) (n ¼ 44)
OR (95% CI) p-Value
Age (years) 68.57 (8.0) 66.18 (8.97) 1.03 (0.96–1.11) 0.372
Gender n (%)
Male 4 (29) 27 (61) Ref. 0.039
Female 10 (71) 17 (39) 3.97 (1.07–14.70)
Inhaled steroid (mcg/day) 400 (0 to 850) 0 (0 to 1000) 1.00 (0.99–1.00) 0.629
Smoking (pack years) 32.57 (23.08) 42.16 (17.75) 0.97 (0.93–1.01) 0.116
FEV1 (l) 0.98 (0.38) 1.48 (0.63) 0.14 (0.03–0.63) 0.011
BMI (kg/m2) 22.73 (3.82) 26.55 (4.29) 0.80 (0.67–0.94) 0.009
SFA FFMI (kg/m2) 15.44 (1.37) 17.77 (2.37) 0.56 (0.37–0.83) 0.005
MAC (cm) 27.27 (3.25) 29.53 (3.58) 0.83 (0.68–0.99) 0.047
IBW (%) 101.72 (13.89) 118.66 (17.29) 0.94 (0.90–0.98) 0.004
Values are mean (SD) unless stated otherwise.
OR ¼ odds ratio. OR41 implies higher probability of osteoporosis, ORo1 implies lower probability of osteoporosis.
Median (interquartile range).
Significant values po0.05.
Table 4 Results of multivariate analyses to examine
the relationship between body composition measured in
the community on osteoporosis after adjusting for risk
factors.
Adjusted OR 95% CI p-Value
BMI (kg/m2) 0.79 0.64–0.98 0.033
SFA FFMI (kg/m2) 0.64 0.39–1.04 0.072
MAC (cm) 0.84 0.67–1.05 0.127
IBW (%) 0.93 0.87–0.99 0.016
Adjusted for age, gender, FEV1, daily dose of inhaled
steroids and smoking pack years.
Significant values po0.05.
C.E. Bolton et al.654the lower the %IBW or BMI measurement, the higher the risk
of osteoporosis. The addition of any of the other body
composition measurements did not improve either model.
The same results are shown using the continuous T scores
as the outcome. The proportion of variation in BMD (using T
scores) explained by the adjusted %IBW model for both the
lumbar spine and hip region, is 28% and 52%, respectively,
and for the adjusted BMI model is 27% and 58%, respectively.Again, the addition of any of the other body composition
measurements did not significantly improve the model.
Predicted probabilities were calculated from the two
adjusted models (%IBW and BMI) The ROC area of the
adjusted %IBW and BMI models were 0.88 (95% CI 0.79–0.97),
indicating a good fit (Figure 1).Discussion
We have reported the utility of various anthropometric
measurements in determining which patients with COPD are
at greater risk of osteoporosis and hence would require a
DXA scan. Based on the measures that can be performed in
the community, BMI and %IBW are the most informative. The
other anthropometric measurements studied did not have a
similar predictive value. Thus, BMI and %IBW may offer a
method of selecting patients for BMD determination.
The important sequelae to osteoporosis, namely hip, wrist
and vertebral fractures are major worldwide problems.
Besides the associated discomfort to the patient, the
superimposed disability to the already respiratory impaired
patient can add to the difficulties encountered, both short
and long term. The fiscal enormity of fractures not only
encompasses the direct costs of inpatient stay and asso-
ciated reparative costs of the fracture but the indirect costs
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Figure 1 Receiver operating characteristic for %IBW and BMI.
BMI and %IBW are adjusted for age, gender, FEV1, daily dose of
inhaled steroids and smoking pack years.
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working days. The respiratory restrictions of COPD may also
complicate or prohibit the anaesthetic procedures asso-
ciated with managing certain fractures. In itself, vertebral
fractures can add to the respiratory dysfunction—reported
as a 10% reduction in FVC18 in patients.
In this population of COPD patients, drawn predominantly
from the community, we identified 24% of our patients as
having osteoporosis, previously undetected, and a further
50% having osteopenia, compared to a previous report 13%
of controls suffering osteoporosis and 22% having osteope-
nia. Other studies have identified evidence of some bone
disease in over 50% of the population,19 others looked
specifically at osteoporosis, found in 33%20 or vertebral
fractures in up to 63% patients.21,22
The introduction of the NICE and the ATS/ERS guidelines
emphasise the ‘‘non-airways’’ elements of COPD and that a
composite picture of COPD includes assessment of exercise
ability, nutritional status and quality of life.9,10 Whilst many
studies present body composition as a ‘‘secondary care’’
issue, there are measures that can be performed in the
community to assess nutritional status and could be
incorporated into the COPD assessment.
The BMI and the related measure of %IBW predicted
osteoporosis in these patients, even allowing for other
traditional risk factors such as age, gender, lung function
and other more controversial factors such as inhaled
corticosteroids. The calculation of %IBW relates the sub-
jects’ weight not only to a height ratio but also to an
assessment of build (based on the wrist circumference) and
therefore requires little training. This measurement ap-
peared to contribute only a minor additional benefit to BMI
alone. Given the more universal utility of BMI, this appears a
more appropriate assessment. Incalzi et al.23 detected a
difference in MAC between those patients with COPD whoalso had osteoporosis or not but failed to demonstrate its
use in predicting osteoporosis. SFA requires training in order
to achieve reliable, reproducible results. Inter-observer
variation and repeatability of such measurements needs to
be borne in mind also, even after training. In addition, as
the calipers reach maximal opening in the obese person, the
precision of calculations by SFA is less. We used a 2 site
evaluation of SFA–FFMI, one of which was a central trunk
measurement. This may not detect other areas of FFM loss
such as lower limb loss in patients which may account for
SFA–FFMI failing to demonstrate what we have previously
shown with DXA-based calculation of FFMI,3 despite the fact
that one person with training performed all the measure-
ments. Therefore the robust measures of FFMI by DEXA body
composition analysis are not achievable with SFA and cannot
be extrapolated to the risk of osteoporosis. Bioelectrical
impedance using validated equipment is one method to
measure FFM although it is expensive and more cumbersome
than other community applied anthropometry tools included
in this study.24 The utility of all of these body composition
parameters in risk stratifying patients other than for bone
disease is beyond the scope of this paper and we advocate
further research to evaluate the inclusion of body composi-
tion risk stratification in community patients.
This work highlights that many body composition para-
meters have been given arbitrary cut-off’s and can vary
across guidelines.9,10,25,26 Variation with guidelines may
reflect the healthy subject populations which differ across
continents and even countries as well as changing socio-
environmental factors with time. The NICE/BTS guidelines
advocate a BMI of 20 kg/m2.9 This demarcation has been
shown to have prognostic significance in mortality.26 More
recently, Celli et al.25 suggested that a BMI ofo21 kg/m2 as
equating to worse survival. We found that the lower 5th
percentile of this South Wales population for BMI was
20.3 kg/m2.
The cause for osteoporosis in COPD patients is likely to be
multifactorial. It cannot be fully explained by smoking
history or by gender. The betamethasone equivalent inhaled
corticosteroid dose was not different between those with
osteoporosis and those without and our patients were
selected for never having received oral maintenance
corticosteroids. Systemic inflammation, catabolic inter-
mediary metabolism, hypogonadism, short course ‘‘rescue’’
oral corticosteroid therapy, periods of bed rest during
exacerbations and physical inactivity are all likely to play
a role.27–30 Identification of milder forms of BMD loss such as
osteopenia may provide an opportunity to readdress nutri-
tional and physical activity optimisation in order to prevent
further deterioration in BMD leading to osteoporosis. Risk of
fracture is a continuum—Marshall et al.31 demonstrated
that for every 1 standard deviation drop in BMD, the risk of
fracture increased by 1.5–2.5 fold. Of note, the presence of
vertebral fracture should necessitate the commencement of
treatment, regardless of BMD.32 None of our patients had
clinical grounds to suspect osteoporosis or vertebral fracture
prior to inclusion in the study. Other measures to limit
fracture risk such as maintaining stability are important—a
factor that can be influenced by peripheral muscle mass and
function, often reduced in patients with COPD.33
Currently, within the UK, initiatives are being undertaken
to improve spirometry usage and interpretation of the
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detailed nutritional and functional assessment need to be
advocated. Targets in COPD are becoming more and more
orientated to early detection and preventative therapy.
COPD by nature is slowly progressive and the earlier the
extent of the disease and its related disabling character-
istics identified, targeted measures could be implemented.
Meanwhile, therapy options in place such as focused
smoking cessation, appropriate exercise prescription and
pulmonary rehabilitation together with optimal manage-
ment to reduce exacerbations are to be commended and
may also confer additional assistance to bone health.
Limitations
This work is based on a small group of identified patients
who were free from chronic oral corticosteroid treatment
and other metabolic, neoplastic and inflammatory disease.
The Royal College of Physicians offers recommendations on
management of the patient on maintenance oral corticos-
teroids, but identifying osteoporosis in the vast majority of
patients with COPD not on maintenance oral corticosteroids
has to date not been addressed.35 In practice, the group we
report is select and further larger studies are warranted to
explore the possibilities and benefits of simple anthropo-
metry in population studies where patients may be on oral
corticosteroids or have additional co-morbidities which may
also affect body composition and BMD.
Conclusion
In conclusion, there is a need to detect osteoporosis in
patients with COPD, where this associated morbidity is
common and present across the spectrum of severity of
airways obstruction. A recognised influence on osteoporosis
is body composition and this study advocates that BMI or
%IBW can identify the high-risk sub-group of patient and
strengthens the advice in guidelines on the use of BMI and
body weight. Similarly, failure of skin fold or MAC to predict
osteoporosis emphasises the current use of BMI. We would
encourage further studies to be performed to incorporate a
nutritional assessment, into the annual review of the patient
with COPD within the community and address targeted
approaches to identify patients who may have concurrent
osteoporosis.
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